查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2069219

精準獸醫市場預測—全球產品/服務、動物種類、技術、應用、最終用戶和地區分析—2034年

Companion Animal Precision Medicine Market Forecasts to 2034 - Global Analysis By Product And Service (Diagnostics, Therapeutics, Software and Data Analytics and Services), Animal Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

全球精準獸醫市場預計到 2026 年將達到 6 億美元，並在預測期內以 13.9% 的複合年成長率成長，到 2034 年達到 17 億美元。

伴侶動物精準醫療是指一種個人化的醫療保健方法，它利用遺傳、基因組、分子、環境和生活方式數據，為每隻伴侶動物量身定做疾病預防、診斷和治療策略。透過分析獨特的生物學特徵和健康狀況，精準醫療能夠實現有針對性的治療性介入、最佳化藥物選擇並改善臨床療效。這種方法能夠增強獸醫的決策能力，支持疾病的早期發現，並促進更有效、更個人化的寵物醫療保健管理。

寵物「擬人化」的趨勢

隨著寵物越來越“擬人化”，寵物飼主對寵物醫療保健的要求也越來越高，他們希望寵物能享受與人類同等的醫療保健標準，包括個人化的診斷和治療方案。寵物飼主越來越將心愛的寵物視為家庭成員，並尋求複雜疾病的先進醫療干預措施。在已開發國家，人們為先進的獸醫服務付費的意願顯著提高。透過社群媒體和線上社區，人們對針對患有癌症和遺傳疾病的寵物的精準醫療方案的認知度也在不斷提高。這些文化轉變正在為高品質的獸醫診斷和標靶治療創造一個極具市場潛力的領域。

獸醫基因組資料庫有限

與人類醫學相比，精準獸醫學的發展受到全面基因組和分子資料庫匱乏的限制。許多伴侶動物品種的參考基因組仍不完整或註釋不完整。犬貓品種的多樣性給建立特定群體的遺傳基準帶來了挑戰。生物標記組合的臨床檢驗需要大規模、成本高且耗時的縱向研究。缺乏標準化的分子診斷方案使得不同獸醫檢查室之間的結果難以解讀。

腫瘤學生物標記的擴展

獸醫腫瘤學是精準醫學領域最具發展前景的領域之一，在基於生物標記的治療方法選擇方面具有巨大潛力。犬類癌症模型與人類癌症具有分子相似性，這使得轉化研究成為可能。檢測循環腫瘤DNA的液態生物檢體技術能夠對寵物進行非侵入性癌症監測。基於分子譜分析，針對人類腫瘤開發的標靶治療正被應用於獸醫領域。寵物飼主與其寵物之間深厚的情感紐帶促使他們願意投資於先進的癌症診斷和個人化治療方案。

監管過程中的不確定性

與人類藥品和診斷產品的監管相比，精準獸藥產品的法規結構仍不完善。許多司法管轄區缺乏針對伴侶動物基因檢測和標靶治療核准流程的明確指南。監管機構難以將新型精準醫療產品納入現有的獸藥產品分類系統。缺乏標準化的臨床檢驗要求也阻礙了創新診斷產品的市場准入。這些監管方面的不確定性可能會延緩產品商業化進程，並增加精準醫療產品開發商的合規成本。

新型冠狀病毒（COVID-19）的影響：

新冠疫情擾亂了獸醫診斷檢查室的運作，並導致學術機構的精準醫療研究計畫延誤。然而，疫情封鎖期間寵物飼養量的激增擴大了尋求高級獸醫服務的患者群體。供應鏈挑戰影響了分子診斷所需專用試劑和耗材的供應。疫情後，寵物飼養量的持續成長帶來了對高品質獸醫護理（包括精準醫療服務）的持續需求。此次危機也加速了數位醫療平台在精準醫療遠距會診的應用。

在預測期內，診斷領域預計將佔據最大的市場佔有率。

鑑於分子和基因檢測在實現精準醫療方法中發揮著至關重要的作用，預計在預測期內，診斷領域將佔據最大的市場佔有率。包括次世代定序、基於PCR的檢測和免疫組織化學在內的診斷平台，能夠提供製定治療策略所需的分子資訊。疾病後續觀察中重複進行的診斷檢測，為企業創造了永續的收入來源。參考實驗室提供全面的診斷檢測方案，為企業進入精準醫療領域提供了途徑。與標靶治療相比，診斷成本更低，這進一步擴大了市場准入範圍。

預計人工智慧和機器學習領域在預測期內將呈現最高的複合年成長率。

在預測期內，人工智慧和機器學習領域預計將呈現最高的成長率，這主要得益於運算分析在解讀複雜的多組體學資料集方面發揮的關鍵作用。人工智慧演算法能夠識別基因組學、蛋白質組學和臨床數據中的模式，從而實現疾病的預測建模。基於獸醫資料集訓練的機器學習模型能夠提高診斷準確性和治療建議的精確度。人工智慧與電子健康記錄的整合能夠支援獸醫進行即時臨床決策。創業投資對獸醫技術的投入正在加速人工智慧驅動的精準醫療平台的發展。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的獸醫研究基礎設施和高昂的寵物醫療費用支出。美國憑藉其龐大的獸醫學院和研究機構網路，在精準醫療研究領域中處於領先地位。領先的人類製藥公司正在將其腫瘤學和遺傳學平台應用於伴侶動物領域。蓬勃發展的寵物保險市場為獲得先進的分子診斷和標靶治療提供了支持。該地區強大的生物技術生態系統正在加速基因組學研究在獸醫臨床產品中的應用。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於伴侶動物數量的成長和獸醫專業基礎設施的完善。中國寵物市場的快速發展催生了對先進獸醫診斷和個人化治療方案的需求。日本成熟的生物技術產業正在支持伴侶動物基因組檢測服務的發展。澳洲強大的動物健康研究體係正為畜牧業和伴侶動物的精準醫療創新做出貢獻。韓國對生物資訊學和基因組學研究的投入正在推動該地區精準醫療生態系統的發展。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性評估）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球精準獸醫市場：依產品與服務分類

  • 診斷
  • 治療
  • 軟體和數據分析
  • 服務

第6章：全球精準獸醫市場：依動物類型分類

  • 狗
  • 貓
  • 馬
  • 其他伴侶動物

第7章：全球精準獸醫市場：依技術分類

  • 基因組學
  • 蛋白質體學
  • 代謝體學
  • 生物資訊學
  • CRISPR和基因編輯
  • 人工智慧和機器學習

第8章：全球精準獸醫市場：依應用領域分類

  • 腫瘤學
  • 循環系統
  • 神經病學
  • 皮膚科
  • 內分泌學
  • 感染疾病
  • 整形外科

第9章：全球精準獸醫市場：依最終用戶分類

  • 動物醫院
  • 專科動物醫院
  • 診斷檢查室
  • 製藥和生物技術公司
  • 學術研究機構

第10章 全球精準獸醫市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • IdeCompanion Animal Precision Medicine Laboratories, Inc.
  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Aratana Therapeutics, Inc.
  • Kindred Biosciences, Inc.
  • Regeneus Ltd.
  • Vetigenics
  • FidoCure
  • One Health Company
Product Code: SMRC37236

According to Stratistics MRC, the Global Companion Animal Precision Medicine Market is accounted for $0.6 billion in 2026 and is expected to reach $1.7 billion by 2034 growing at a CAGR of 13.9% during the forecast period. Companion Animal Precision Medicine refers to a personalized veterinary healthcare approach that uses genetic, genomic, molecular, environmental, and lifestyle data to tailor disease prevention, diagnosis, and treatment strategies for individual companion animals. By analyzing unique biological characteristics and health profiles, precision medicine enables targeted therapeutic interventions, optimized medication selection, and improved clinical outcomes. This approach enhances veterinary decision-making, supports early disease detection, and promotes more effective and individualized healthcare management for pets.

Market Dynamics:

Driver:

Pet humanization trend

The deepening humanization of companion animals drives pet owners to demand healthcare standards equivalent to human medicine, including personalized diagnostic and therapeutic approaches. Pet owners increasingly view their animals as family members and seek advanced medical interventions for complex conditions. The willingness to pay for sophisticated veterinary services has expanded substantially across developed economies. Social media and online communities amplify awareness of precision medicine options for pets with cancer and genetic disorders. This cultural shift creates a receptive market for premium veterinary diagnostics and targeted therapeutics.

Restraint:

Limited veterinary genomic databases

The development of precision medicine for companion animals is constrained by the limited availability of comprehensive genomic and molecular databases compared to human medicine. Reference genomes for many companion animal breeds remain incomplete or poorly annotated. The diversity of dog and cat breeds creates challenges in establishing population-specific genetic baselines. Clinical validation of biomarker panels requires extensive longitudinal studies that are costly and time-intensive. The absence of standardized molecular diagnostic protocols complicates result interpretation across different veterinary laboratories.

Opportunity:

Oncology biomarker expansion

Veterinary oncology represents the most promising application area for precision medicine with substantial opportunities for biomarker-driven therapeutic selection. Canine cancer models share molecular similarities with human cancers, enabling translational research approaches. Liquid biopsy technologies for circulating tumor DNA detection enable non-invasive cancer monitoring in pets. Targeted therapeutics developed for human oncology are being repurposed for veterinary applications based on molecular profiling. The emotional bond between pet owners and their animals drives the willingness to invest in advanced cancer diagnostics and personalized treatment protocols.

Threat:

Regulatory pathway uncertainty

The regulatory frameworks for veterinary precision medicine products remain underdeveloped compared to human pharmaceutical and diagnostic regulations. The approval pathways for companion animal genetic tests and targeted therapeutics lack clear guidance in many jurisdictions. Regulatory agencies struggle to categorize novel precision medicine products within existing veterinary product classifications. The absence of standardized clinical validation requirements creates market entry barriers for innovative diagnostics. These regulatory uncertainties may delay product commercialization and increase compliance costs for precision medicine developers.

Covid-19 Impact:

The COVID-19 pandemic disrupted veterinary diagnostic laboratory operations and delayed precision medicine research programs across academic institutions. However, the surge in pet adoption during lockdown periods created a larger patient population for advanced veterinary services. Supply chain challenges affected the availability of specialized reagents and consumables for molecular diagnostics. Post-pandemic, the sustained increase in pet ownership has generated lasting demand for premium veterinary healthcare, including precision medicine services. The crisis accelerated the adoption of digital health platforms that support remote delivery of precision medicine consultations.

The diagnostics segment is expected to be the largest during the forecast period

The diagnostics segment is expected to account for the largest market share during the forecast period, due to the foundational role of molecular and genetic testing in enabling precision medicine approaches. Diagnostic platforms, including next-generation sequencing, PCR-based assays, and immunohistochemistry, provide the molecular information required for therapeutic decision-making. The recurring nature of diagnostic testing throughout disease monitoring generates sustained revenue streams. Reference laboratories offer comprehensive diagnostic panels that serve as entry points for precision medicine engagement. The lower cost point of diagnostics compared to targeted therapeutics facilitates broader market accessibility.

The AI and machine learning segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the AI and machine learning segment is predicted to witness the highest growth rate, driven by the critical role of computational analysis in interpreting complex multi-omics datasets. Artificial intelligence algorithms identify patterns in genomic, proteomic, and clinical data that enable predictive disease modeling. Machine learning models trained on veterinary datasets improve diagnostic accuracy and treatment recommendation precision. The integration of AI with electronic health records supports real-time clinical decision support for veterinarians. Venture capital investment in veterinary health technology accelerates the development of AI-powered precision medicine platforms.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to advanced veterinary research infrastructure and high pet healthcare expenditure. The United States leads with an extensive network of veterinary colleges and research institutions conducting precision medicine studies. Major human pharmaceutical companies are repurposing oncology and genetic platforms for companion animal applications. Strong pet insurance markets support access to advanced molecular diagnostics and targeted therapies. The region's robust biotechnology ecosystem facilitates rapid translation of genomic research into veterinary clinical products.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to expanding companion animal ownership and developing veterinary specialty infrastructure. China's rapidly growing pet market creates demand for advanced veterinary diagnostics and personalized treatment approaches. Japan's established biotechnology sector supports the development of companion animal genomic testing services. Australia's strong animal health research community contributes to precision medicine innovation for livestock and companion species. South Korea's investment in bioinformatics and genomics research accelerates the regional precision medicine ecosystem.

Key players in the market

Some of the key players in Companion Animal Precision Medicine Market include Zoetis Inc., Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Merck & Co., Inc., IdeCompanion Animal Precision Medicine Laboratories, Inc., Roche Holding AG, Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Illumina, Inc., Aratana Therapeutics, Inc., Kindred Biosciences, Inc., Regeneus Ltd., Vetigenics, FidoCure and One Health Company.

Key Developments:

In June 2026, Zoetis Inc. launched a comprehensive canine oncology genomic profiling service enabling veterinarians to identify actionable mutations and select targeted therapies for individual cancer patients.

In May 2026, Illumina, Inc. expanded its veterinary sequencing platform to include whole-genome analysis for hereditary disease screening across multiple companion animal breeds with clinical-grade accuracy.

In March 2026, FidoCure partnered with a national veterinary oncology network to deploy its precision medicine platform, matching canine cancer patients with clinically validated targeted therapeutic protocols.

Product and Services Covered:

  • Diagnostics
  • Therapeutics
  • Software and Data Analytics
  • Services

Animal Types Covered:

  • Dogs
  • Cats
  • Horses
  • Other Companion Animals

Technologies Covered:

  • Genomics
  • Proteomics
  • Metabolomics
  • Bioinformatics
  • CRISPR and Gene Editing
  • AI and Machine Learning

Applications Covered:

  • Oncology
  • Cardiology
  • Neurology
  • Dermatology
  • Endocrinology
  • Infectious Diseases
  • Orthopedics

End Users Covered:

  • Veterinary Hospitals
  • Specialty Veterinary Clinics
  • Diagnostic Laboratories
  • Pharmaceutical and Biotech Companies
  • Academic Research Institutes

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Companion Animal Precision Medicine Market, By Product And Service

  • 5.1 Diagnostics
  • 5.2 Therapeutics
  • 5.3 Software and Data Analytics
  • 5.4 Services

6 Global Companion Animal Precision Medicine Market, By Animal Type

  • 6.1 Dogs
  • 6.2 Cats
  • 6.3 Horses
  • 6.4 Other Companion Animals

7 Global Companion Animal Precision Medicine Market, By Technology

  • 7.1 Genomics
  • 7.2 Proteomics
  • 7.3 Metabolomics
  • 7.4 Bioinformatics
  • 7.5 CRISPR and Gene Editing
  • 7.6 AI and Machine Learning

8 Global Companion Animal Precision Medicine Market, By Application

  • 8.1 Oncology
  • 8.2 Cardiology
  • 8.3 Neurology
  • 8.4 Dermatology
  • 8.5 Endocrinology
  • 8.6 Infectious Diseases
  • 8.7 Orthopedics

9 Global Companion Animal Precision Medicine Market, By End User

  • 9.1 Veterinary Hospitals
  • 9.2 Specialty Veterinary Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Pharmaceutical and Biotech Companies
  • 9.5 Academic Research Institutes

10 Global Companion Animal Precision Medicine Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Zoetis Inc.
  • 13.2 Elanco Animal Health Incorporated
  • 13.3 Boehringer Ingelheim International GmbH
  • 13.4 Merck & Co., Inc.
  • 13.5 IdeCompanion Animal Precision Medicine Laboratories, Inc.
  • 13.6 Roche Holding AG
  • 13.7 Novartis AG
  • 13.8 Pfizer Inc.
  • 13.9 Bristol-Myers Squibb Company
  • 13.10 Thermo Fisher Scientific Inc.
  • 13.11 Illumina, Inc.
  • 13.12 Aratana Therapeutics, Inc.
  • 13.13 Kindred Biosciences, Inc.
  • 13.14 Regeneus Ltd.
  • 13.15 Vetigenics
  • 13.16 FidoCure
  • 13.17 One Health Company

List of Tables

  • Table 1 Global Companion Animal Precision Medicine Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Companion Animal Precision Medicine Market Outlook, By Product And Service (2023-2034) ($MN)
  • Table 3 Global Companion Animal Precision Medicine Market Outlook, By Diagnostics (2023-2034) ($MN)
  • Table 4 Global Companion Animal Precision Medicine Market Outlook, By Therapeutics (2023-2034) ($MN)
  • Table 5 Global Companion Animal Precision Medicine Market Outlook, By Software and Data Analytics (2023-2034) ($MN)
  • Table 6 Global Companion Animal Precision Medicine Market Outlook, By Services (2023-2034) ($MN)
  • Table 7 Global Companion Animal Precision Medicine Market Outlook, By Animal Type (2023-2034) ($MN)
  • Table 8 Global Companion Animal Precision Medicine Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 9 Global Companion Animal Precision Medicine Market Outlook, By Cats (2023-2034) ($MN)
  • Table 10 Global Companion Animal Precision Medicine Market Outlook, By Horses (2023-2034) ($MN)
  • Table 11 Global Companion Animal Precision Medicine Market Outlook, By Other Companion Animals (2023-2034) ($MN)
  • Table 12 Global Companion Animal Precision Medicine Market Outlook, By Technology (2023-2034) ($MN)
  • Table 13 Global Companion Animal Precision Medicine Market Outlook, By Genomics (2023-2034) ($MN)
  • Table 14 Global Companion Animal Precision Medicine Market Outlook, By Proteomics (2023-2034) ($MN)
  • Table 15 Global Companion Animal Precision Medicine Market Outlook, By Metabolomics (2023-2034) ($MN)
  • Table 16 Global Companion Animal Precision Medicine Market Outlook, By Bioinformatics (2023-2034) ($MN)
  • Table 17 Global Companion Animal Precision Medicine Market Outlook, By CRISPR and Gene Editing (2023-2034) ($MN)
  • Table 18 Global Companion Animal Precision Medicine Market Outlook, By AI and Machine Learning (2023-2034) ($MN)
  • Table 19 Global Companion Animal Precision Medicine Market Outlook, By Application (2023-2034) ($MN)
  • Table 20 Global Companion Animal Precision Medicine Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 21 Global Companion Animal Precision Medicine Market Outlook, By Cardiology (2023-2034) ($MN)
  • Table 22 Global Companion Animal Precision Medicine Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 23 Global Companion Animal Precision Medicine Market Outlook, By Dermatology (2023-2034) ($MN)
  • Table 24 Global Companion Animal Precision Medicine Market Outlook, By Endocrinology (2023-2034) ($MN)
  • Table 25 Global Companion Animal Precision Medicine Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 26 Global Companion Animal Precision Medicine Market Outlook, By Orthopedics (2023-2034) ($MN)
  • Table 27 Global Companion Animal Precision Medicine Market Outlook, By End User (2023-2034) ($MN)
  • Table 28 Global Companion Animal Precision Medicine Market Outlook, By Veterinary Hospitals (2023-2034) ($MN)
  • Table 29 Global Companion Animal Precision Medicine Market Outlook, By Specialty Veterinary Clinics (2023-2034) ($MN)
  • Table 30 Global Companion Animal Precision Medicine Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 31 Global Companion Animal Precision Medicine Market Outlook, By Pharmaceutical and Biotech Companies (2023-2034) ($MN)
  • Table 32 Global Companion Animal Precision Medicine Market Outlook, By Academic Research Institutes (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.